Analysts expect Medline to report Q1 2026 revenue of $7.16 billion and EPS of $0.29, with the stock currently trading at $44.75 against an average price target of $50.62.
Investors are primarily focused on the recovery of net profit margins following a recent decline to 4.1% and the operational launch of the Symbotic AI-powered warehouse automation partnership. Recent performance has been marked by strong revenue growth of 14.8% in Q4, although the company is currently navigating an FDA warning letter regarding quality control issues. Despite macro headwinds from tariffs, Medline’s robust prime vendor contract wins—exceeding targets by 2.5x in 2025—provide a significant growth pipeline for the fiscal year.